Show simple item record

dc.contributor.authorVollm, Birgit A.
dc.date.accessioned2017-09-20T16:00:17Z
dc.date.available2017-09-20T16:00:17Z
dc.date.issued2010
dc.identifier.citationLieb, K., Vollm, B. A., Rucker, G., Timmer, A. & Stoffers, J. M. (2010). Pharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials. The British Journal of Psychiatry, 196 (1), pp.4-12.
dc.identifier.other10.1192/bjp.bp.108.062984
dc.identifier.urihttp://hdl.handle.net/20.500.12904/9442
dc.description.abstractBackground: Many patients with borderline personality disorder receive pharmacological treatment, but there is uncertainty about the usefulness of such therapies. Aims: To evaluate the evidence of effectiveness of pharmacotherapy in treating different facets of the psychopathology of borderline personality disorder. Method: A Cochrane Collaboration systematic review and meta-analysis of randomised comparisons of drug v. placebo, drug v. drug, or single drug v. combined drug treatment in adult patients with borderline personality disorder was conducted. Primary outcomes were overall disorder severity as well as specific core symptoms. Secondary outcomes comprised associated psychiatric pathology and drug tolerability. Results: Twenty-seven trials were included in which first- and second-generation antipsychotics, mood stabilisers, antidepressants and omega-3 fatty acids were tested. Most beneficial effects were found for the mood stabilisers topiramate, lamotrigine and valproate semisodium, and the second-generation antipsychotics aripiprazole and olanzapine. However, the robustness of findings is low, since they are based mostly on single, small studies. Selective serotonin reuptake inhibitors so far lack high-level evidence of effectiveness. Conclusions: The current evidence from randomised controlled trials suggests that drug treatment, especially with mood stabilisers and second-generation antipsychotics, may be effective for treating a number of core symptoms and associated psychopathology, but the evidence does not currently support effectiveness for overall severity of borderline personality disorder. Pharmacotherapy should therefore be targeted at specific symptoms.
dc.description.urihttps://www.cambridge.org/core/journals/the-british-journal-of-psychiatry/article/pharmacotherapy-for-borderline-personality-disorder-cochrane-systematic-review-of-randomised-trials/54811BAC35780F663AAE309B4CB4F48E
dc.subjectBorderline personality disorder
dc.titlePharmacotherapy for borderline personality disorder: Cochrane systematic review of randomised trials
dc.typeArticle


This item appears in the following Collection(s)

Show simple item record